Over the past four years, few topics in women's health and personal care have generated as much anxiety, media coverage, and legal advertising as the link between chemical hair straighteners and reproductive cancers.
Billboards and social media feeds are flooded with law-firm advertisements asking: "Did you use hair relaxers and get diagnosed with uterine cancer or fibroids?" Meanwhile, health-system summaries often repeat frightening relative risk multiples without providing absolute numbers, and beauty blogs frequently assert that the FDA has already banned toxic straightening chemicals.
For the millions of women—disproportionately Black and Brown women—who have used chemical relaxers or salon keratin smoothing treatments for decades, this information landscape creates acute health anxiety without clear medical guidance.
To separate established epidemiological evidence from litigation marketing, one must examine what the peer-reviewed cohort studies actually measured, what they were methodologically incapable of measuring, and where federal regulation truly stands:
- The Core Relative Finding Is Real: In the NIH-funded Sister Study (2022), following 33,947 women over an average of 10.9 years, participants who used chemical hair straighteners more than 4 times in the prior year had 2.55 times the rate of uterine cancer compared to never-users (HR 2.55, 95% CI 1.46–4.45).
- Absolute Risk Remains Statistically Small: Because uterine cancer is relatively uncommon, a 2.55-fold increase translates to an absolute risk of approximately 4.05% by age 70 for frequent users, compared to 1.64% for never-users—an absolute difference of roughly 2.4 percentage points. Across nearly 34,000 women followed for a decade, there were 378 total cases.
- Hair Dyes and Perms Showed No Association: In the exact same cohort, permanent hair dyes, semi-permanent dyes, bleach, highlights, and perms showed no association with uterine cancer, indicating that the signal is specific to straightening formulations rather than a generic artifact of salon chemical exposure.
- No Study Has Ever Named a "Safe" or "Dangerous" Brand: The published epidemiological studies collected self-reported broad product categories ("straighteners, relaxers, or pressing products") used in the prior 12 months. Zero brand names, specific chemical formulations, pH levels, or ingredient concentrations were tracked. Any list claiming "these specific relaxers cause cancer" is fabricated from litigation filing lists, not scientific literature.
- Two Completely Different Chemistries Are Conflated: Traditional chemical relaxers (lye/sodium hydroxide and no-lye/calcium hydroxide) work by caustic alkaline denaturation on the scalp. Salon smoothing treatments (Brazilian Blowout / keratin treatments) work by heat-activated crosslinking that releases gaseous formaldehyde into the air.
- The FDA Has NOT Banned Formaldehyde: Despite widespread news reports, the FDA has not published a proposed or final rule banning formaldehyde in hair straighteners. The regulatory proposal remains an unpublished agenda item (RIN 0910-AI83) whose target date for even issuing a draft proposal has slipped repeatedly to November 2026.
Direct Answer: Am I at Risk, and Has Anything Been Banned?
If you used chemical hair relaxers or salon straightening treatments for years and are wondering what this means for your personal health:
┌─────────────────────────────────────────────────────────────────────────────┐
│ HAIR RELAXERS & CANCER: THE ESSENTIAL FACTS │
├───────────────────┬─────────────────────────────────────────────────────────┤
│ Epidemiological │ Sister Study (33,947 women): Frequent straightener use │
│ Finding │ (>4x/yr) associated with HR 2.55 for uterine cancer. │
│ │ Black Women's Health Study (2023) agreed only among │
│ │ postmenopausal women; its overall estimate was null. │
├───────────────────┼─────────────────────────────────────────────────────────┤
│ Absolute Risk │ Baseline lifetime uterine cancer risk: ~1.64% by age 70 │
│ Translation │ Frequent user estimated lifetime risk: ~4.05% by age 70 │
│ │ (Absolute difference: ~2.4 percentage points) │
├───────────────────┼─────────────────────────────────────────────────────────┤
│ Product Specifics │ ZERO brand names or specific ingredients were tracked │
│ │ in the cohort studies; no "safe brand" list exists. │
├───────────────────┼─────────────────────────────────────────────────────────┤
│ FDA Regulatory │ NOTHING IS BANNED. FDA agenda item RIN 0910-AI83 is in │
│ Status (Aug 2026) │ Proposed Rule Stage; target NPRM date: November 2026. │
├───────────────────┼─────────────────────────────────────────────────────────┤
│ Clinical Action │ Routine screening (ultrasound/biopsy) is NOT indicated │
│ for Users │ for asymptomatic women. Promptly evaluate ANY abnormal │
│ │ postmenopausal bleeding or irregular heavy bleeding. │
└───────────────────┴─────────────────────────────────────────────────────────┘
The association between frequent straightener use and uterine cancer is statistically significant in the Sister Study, and a second independent cohort of Black women found the same direction of effect among postmenopausal women — though its overall estimate did not reach significance. However, the absolute likelihood that any individual user will develop uterine cancer remains low.
There is no medical screening test (such as routine transvaginal ultrasound or endometrial biopsy) recommended for asymptomatic former or current relaxer users. The single most important medical instruction is to seek immediate evaluation from a gynecologist if you develop abnormal uterine bleeding, postmenopausal spotting, or severe pelvic pain.
On the regulatory side, no federal ban is in effect. The FDA's proposed rule targets formaldehyde in heat-activated salon smoothing products—not traditional alkaline relaxers—and that rule has not even been published as a formal proposal.
What the Sister Study Actually Found: The Numbers Behind the Headlines
The benchmark study that launched the modern debate was published in December 2022 by Chang and colleagues from the National Institute of Environmental Health Sciences (NIEHS) in the Journal of the National Cancer Institute (PMID 36245087).
┌─────────────────────────────────────────────────────────────────────────────┐
│ THE SISTER STUDY (CHANG ET AL. 2022) DATA AT A GLANCE │
├───────────────────────────────────┬─────────────────────────────────────────┤
│ Cohort Size & Eligibility │ 33,947 US women aged 35–74 with intact │
│ │ uterus at baseline (enrolled 2003–2009) │
├───────────────────────────────────┼─────────────────────────────────────────┤
│ Follow-Up Duration │ Average 10.9 years (378 incident cases) │
├───────────────────────────────────┼─────────────────────────────────────────┤
│ Ever-Use of Straighteners (12 mo) │ Hazard Ratio: 1.80 (95% CI: 1.12 – 2.88)│
├───────────────────────────────────┼─────────────────────────────────────────┤
│ Frequent Use (>4 times in 12 mo) │ Hazard Ratio: 2.55 (95% CI: 1.46 – 4.45)│
│ │ Dose-response trend: P = .002 │
├───────────────────────────────────┼─────────────────────────────────────────┤
│ Permanent Dyes (ever use) │ Hazard Ratio: 0.90 (0.74 – 1.11); null │
├───────────────────────────────────┼─────────────────────────────────────────┤
│ Body Waves / Perms (ever use) │ Hazard Ratio: 1.01 (0.75 – 1.37); null │
└───────────────────────────────────┴─────────────────────────────────────────┘
The Dose-Response Relationship
The study established a clear dose-response relationship:
- Women who reported any use of chemical straighteners in the past 12 months had an 80% higher rate of uterine cancer (HR 1.80).
- Women who reported frequent use (more than 4 times per year) had a 155% higher rate (HR 2.55).
- Non-users of straighteners had the lowest incidence.
The Negative Control Group
Crucially, the investigators evaluated other common chemical hair treatments within the same patient cohort. For ever-use versus never-use, every estimate straddled the null:
- Permanent hair dyes: HR 0.90 (95% CI 0.74–1.11)
- Semi-permanent dyes: HR 0.94 (95% CI 0.72–1.24)
- Temporary dyes: HR 1.25 (95% CI 0.88–1.78)
- Bleach: HR 0.77 (95% CI 0.53–1.11)
- Highlights: HR 0.86 (95% CI 0.68–1.10)
- Perms / body waves: HR 1.01 (95% CI 0.75–1.37)
The fact that perms (which use ammonium thioglycolate to curl hair) and oxidative dyes showed no elevated risk strongly indicates that the signal is not a generic artifact of chemical salon exposure, but is linked to specific chemical compounds or application practices unique to straightening products.
Relative Risk vs. Absolute Risk: Putting 378 Cases in Perspective
In public health communication, reporting only relative risk (e.g., "relaxers double your cancer risk") without reporting absolute risk creates disproportionate panic.
[Cumulative Risk of Uterine Cancer by Age 70]
Never-Users of Straighteners Frequent Straightener Users (>4x/yr)
┌──────────────────────────┐ ┌──────────────────────────┐
│ │ │ │
│ 1.64% Cumulative Risk │ │ 4.05% Cumulative Risk │
│ (~16 in 1,000 women) │ │ (~40 in 1,000 women) │
│ │ │ │
└──────────────────────────┘ └──────────────────────────┘
▲ ▲
└──────────────────┬──────────────────┘
│
Absolute Increase:
~2.41 percentage points
(~24 extra cases per 1,000)
- Baseline Absolute Risk: In the United States general population, uterine cancer (primarily endometrial adenocarcinoma) is relatively uncommon, with a lifetime risk of approximately 3.1% across all women.
- Study Population Projections: In the Sister Study model, the estimated cumulative risk of developing uterine cancer by age 70 was:
- 1.64% for women who never used chemical straighteners.
- 4.05% for women who used straighteners frequently (>4 times per year).
- The Absolute Gap: While a hazard ratio of 2.55 represents a substantial relative increase, the absolute difference is approximately 2.41 additional cases per 100 women by age 70.
Out of 33,947 women followed for over a decade, 378 total cases of uterine cancer developed across the entire study population. Over 98% of the women in the cohort did not develop uterine cancer during the study period.
What the Studies Did NOT Measure: Why Nobody Can Name a "Safe" Brand
A primary driver of consumer frustration is searching for "which relaxers cause cancer" and finding conflicting lists published by plaintiff law firms.
To understand why these lists are scientifically meaningless, one must inspect the Methods section of the published literature:
┌─────────────────────────────────────────────────────────────────────────────┐
│ THE EXPOSURE DATA GAP IN COHORT RESEARCH │
├─────────────────────────────────────────────────────────────────────────────┤
│ 1. Self-Reported Bundled Categories: Questionnaires asked: "In the past 12 │
│ months, how often did you use: Straighteners, relaxers, or pressing │
│ products?" All three distinct product types were grouped together. │
│ │
│ 2. Zero Brand Tracking: Studies did NOT record whether a participant used │
│ Dark & Lovely, Motions, Just for Me, ORS Olive Oil, Brazilian Blowout, │
│ or custom salon preparations. │
│ │
│ 3. Zero Chemical Assays: Studies did NOT test products for formaldehyde, │
│ phthalates, parabens, sodium hydroxide, or heavy metals. │
│ │
│ 4. No Lifetime Duration: The primary exposure metric was frequency in the │
│ 12 months prior to enrollment, not cumulative lifetime applications. │
└─────────────────────────────────────────────────────────────────────────────┘
Because epidemiologists never gathered brand-level data, there is zero scientific evidence that Brand A is more dangerous than Brand B, or that Brand C is a "safe alternative."
When law firms list specific brand names in mass-tort filings, they are listing products historically marketed by major cosmetic conglomerates that had high market share—not products individually isolated in laboratory toxicology trials.
Two Completely Different Chemistries: Hydroxide Relaxers vs. Formaldehyde Smoothing
In both media coverage and litigation, two fundamentally different chemical hair processes are frequently mashed into a single category. Understanding their distinct mechanisms is critical:
┌─────────────────────────────────────────────────────────────────────────────┐
│ CHEMICAL RELAXERS VS. FORMALDEHYDE SMOOTHING │
├───────────────────┬────────────────────────────┬────────────────────────────┤
│ Category │ 1. Traditional Relaxers │ 2. Salon Smoothing / │
│ │ (Lye & No-Lye) │ Keratin Treatments │
├───────────────────┼────────────────────────────┼────────────────────────────┤
│ Primary Actives │ Sodium Hydroxide (Lye); │ Methylene Glycol; Form- │
│ │ Calcium Hydroxide + │ aldehyde; Glyoxylic Acid; │
│ │ Guanidine Carbonate │ Oxoacetamide Carbocysteine │
├───────────────────┼────────────────────────────┼────────────────────────────┤
│ pH Level │ Extremely Alkaline │ Acidic to Neutral │
│ │ (pH 12.0 – 14.0) │ (pH 1.5 – 6.0) │
├───────────────────┼────────────────────────────┼────────────────────────────┤
│ Application Route │ Scalp-level application │ Applied 0.5" from scalp; │
│ │ directly to hair roots │ heated with 450°F flatiron │
├───────────────────┼────────────────────────────┼────────────────────────────┤
│ Exposure Vector │ Transdermal absorption │ Respiratory inhalation │
│ │ via scalp micro-fissures │ of volatile gaseous plume │
├───────────────────┼────────────────────────────┼────────────────────────────┤
│ Target of Pending │ NOT covered by pending │ THE SOLE TARGET of FDA │
│ FDA Ban │ FDA formaldehyde rule │ proposed rule RIN 0910-AI83│
└───────────────────┴────────────────────────────┴────────────────────────────┘
1. Traditional Chemical Relaxers (Lye & No-Lye)
Traditional relaxers work through lanthionization—the extreme alkaline pH (12 to 14) breaks the strong disulfide bonds (cystine cross-links) inside the hair cortex, converting cystine to lanthionine and permanently straightening the natural curl pattern.
- The Scalp Vector: Because relaxers are applied directly to new hair growth at the scalp, the harsh alkaline chemicals frequently cause localized tingling, chemical burns, epidermal ulceration, and scalp micro-fissures.
- The Systemic Hypothesis: These scalp micro-lesions bypass the protective epidermal stratum corneum barrier, facilitating the systemic transdermal absorption of endocrine-disrupting chemicals (EDCs)—including phthalates (used as plasticizers and fragrances), parabens (preservatives), and bisphenols—which can bind estrogen and progesterone receptors in uterine tissue.
- Scalp Pathology: For details on how chronic chemical relaxer use interacts with genetic predisposition in scarring hair loss, see our clinical guide on central centrifugal cicatricial alopecia (CCCA) and tension-related loss in traction alopecia.
2. Salon Smoothing / Keratin Treatments (Formaldehyde-Releasing)
Marketed as "keratin treatments" or "Brazilian smoothing," these products do not break disulfide bonds with lye. Instead, they coat the hair in hydrolyzed keratin and a chemical cross-linker—most commonly methylene glycol (the liquid hydrate of formaldehyde).
- The Thermal Activation: When the stylist blows dry the hair and clamps a 450°F (232°C) flat iron over each strand, heat drives the dehydration reaction, converting liquid methylene glycol into volatile gaseous formaldehyde. The gas crosslinks the keratin sheath around the hair shaft, locking it in a sleek, frizz-free alignment for 3 to 5 months.
- The Respiratory Vector: Formaldehyde is an established IARC Group 1 human carcinogen (linked to nasopharyngeal cancer and leukemia). The primary exposure during keratin treatments is respiratory inhalation of toxic vapors by both the salon client and salon staff (see our occupational safety analysis on laser plume and smoke evacuation safety and our dataset evaluation in FDA cosmetic adverse event reports).
The Replication Picture: Independent Cohorts and Follow-Up Data
Scientific consensus requires replication across independent research populations. Since 2022, several landmark studies have expanded the evidence base:
┌─────────────────────────────────────────────────────────────────────────────┐
│ THE EXPANDED EPIDEMIOLOGICAL TIMELINE │
├─────────────────────────────────────────────────────────────────────────────┤
│ 1. Chang et al. (JNCI 2022; PMID 36245087) — The Sister Study: │
│ - Found HR 2.55 for uterine cancer with frequent straightener use. │
│ │
│ 2. Bertrand et al. (Environ Res 2023; PMID 37821068) — Black Women's │
│ Health Study (BWHS), an independent prospective cohort of Black women: │
│ - Overall heavy use (>=15 yrs, >=5x/yr) was NULL: HR 1.18 (0.81-1.71). │
│ - Among POSTMENOPAUSAL women only: moderate use HR 1.60 (1.01-2.53), │
│ heavy use HR 1.64 (1.01-2.64), >=20 yrs of use HR 1.71 (1.08-2.72). │
│ - Results among premenopausal women were null. │
│ │
│ 3. Ogunsina et al. (Environ Health Perspect 2025; PMID 39808082): │
│ - Extended Sister Study analysis to Uterine Leiomyomas (Fibroids). │
│ - Demonstrated positive association between straightener frequency and │
│ both prevalent and incident fibroids among Black participants. │
│ │
│ 4. Bailey et al. (JNCI 2026; PMID 41022397 / PMC12487841): │
│ - Sister Study, 46,287 women, median 13.1 years of follow-up. │
│ - Extended the question BEYOND hormone-sensitive organs and found │
│ elevated estimates for pancreatic cancer HR 2.66 (1.25-5.66) and │
│ thyroid cancer HR 1.71 (1.01-2.89); non-Hodgkin lymphoma HR 1.62 │
│ (0.94-2.80) and kidney HR 1.60 (0.76-3.36) were imprecise. │
│ - Remaining cancer types were near 1.00. Little evidence of dose │
│ response, and the authors call the findings unconfirmed. │
└─────────────────────────────────────────────────────────────────────────────┘
The follow-up by Bertrand and colleagues (2023) in the Black Women's Health Study (BWHS) matters because it evaluated a dedicated cohort of Black women rather than a mostly-white cohort. It is important to read what it actually found. The headline comparison — heavy use versus never or light use across the whole cohort — was not statistically significant (HR 1.18, 95% CI 0.81–1.71). The significant results appeared only when the analysis was restricted to postmenopausal women, where moderate use, heavy use, and twenty or more years of use all produced hazard ratios between 1.60 and 1.71 with confidence intervals that just cleared 1.0. Among premenopausal women the results were null.
That is meaningful support, but it is weaker and more conditional than "replicated," and any page that tells you two large cohorts simply agree is flattening the picture. What the two studies share is a direction of effect and a dose-response pattern concentrated in longer, heavier, later-life exposure — not an identical result.
The Ogunsina 2025 analysis extended the Sister Study to uterine fibroids, which matters because fibroids are vastly more common than uterine cancer and drive an enormous amount of real-world gynecologic morbidity, hysterectomy, and anemia — particularly among Black women.
The Bailey 2026 analysis is the one most often mis-summarized. It is frequently described as having cleared straighteners of any risk outside hormone-sensitive organs. It did not. It reported elevated estimates for pancreatic cancer (HR 2.66) and thyroid cancer (HR 1.71), with imprecise signals for non-Hodgkin lymphoma and kidney cancer. The authors themselves flag that there was little evidence of dose response and that the findings need confirmation — so these should be read as unconfirmed leads, not as established risks. But the honest summary is that the non-reproductive question is open, not closed.
Has the FDA Banned Formaldehyde? The True Rulemaking Record
One of the most persistent falsehoods on social media is that the FDA banned formaldehyde in hair straighteners in 2024.
The official federal rulemaking record shows that nothing has been banned:
[The Federal Rulemaking Timeline: Unified Agenda Item RIN 0910-AI83]
Oct 2023 April 2024 July 2024 Nov 2026 (Current Target)
───●────────────────●────────────────●──────────────────●────────►
FDA announces Initial target Target date Proposed Rule (NPRM)
intent to ban slips without slips a second target date; NO RULE
formaldehyde action time YET PUBLISHED
The Exact Regulatory Record (reginfo.gov / Federal Register)
- Rule Title: Use of Formaldehyde and Formaldehyde-Releasing Chemicals as an Ingredient in Hair Smoothing Products or Hair Straightening Products
- Agency: Department of Health and Human Services (HHS) / Food and Drug Administration (FDA) / Center for Food Safety and Applied Nutrition (CFSAN)
- Regulation Identifier Number (RIN): 0910-AI83
- Current Stage: Proposed Rule Stage
- Legal Authority: 21 U.S.C. 361 (Adulterated Cosmetics) and 21 U.S.C. 371 (Regulations and Hearings); 21 CFR Part 700
- Current Timetable Target: Notice of Proposed Rulemaking (NPRM) targeted for November 2026
- Federal Register Status: Searches of the Federal Register public API for
formaldehyde hair,hair smoothing, andformaldehyde-releasingreturn zero published proposed or final rule documents.
Why the Rule Is Taking So Long
Under the Food, Drug, and Cosmetic Act and the newly enacted Modernization of Cosmetics Regulation Act (for broader context, see our analysis on MoCRA deadlines and pending FDA cosmetic rules), cosmetics do not undergo FDA premarket approval.
To ban an ingredient, the FDA must undergo lengthy notice-and-comment rulemaking, prove safety hazards across economic impact assessments, and defend against potential commercial litigation.
What the Proposed Rule Would and Would Not Cover
- What it WOULD ban: The rule proposes to prohibit formaldehyde and formaldehyde-releasing chemicals (specifically naming methylene glycol) in hair smoothing or straightening products that are applied to hair and heated under their conditions of use.
- What it would NOT ban: The rule does not cover traditional sodium hydroxide (lye), calcium hydroxide, or guanidine carbonate chemical relaxers.
Social Context Without Stigma: Why This Disproportionately Affects Black Women
In epidemiology, discussing risk factors without social context can inadvertently sound like victim-blaming.
The exposure gap is stark and well documented. In the Sister Study cohort, 66% of Black participants reported straightening or relaxing their hair in the year before enrollment, compared with 25% of Hispanic and Latina participants and 1.3% of non-Hispanic white participants. Roughly 60% of everyone in that cohort who reported using straighteners was a Black woman. Lifetime ever-use estimates among Black women in other US surveys run far higher still. This disparity is not arbitrary:
┌─────────────────────────────────────────────────────────────────────────────┐
│ STRUCTURAL AND CULTURAL CONTEXT │
├─────────────────────────────────────────────────────────────────────────────┤
│ 1. Historical Workplace & Grooming Discrimination: For decades, natural │
│ Afro-textured hair (coils, braids, locs, afros) was deemed │
│ "unprofessional" or in violation of corporate and military dress codes. │
│ │
│ 2. The CROWN Act: The Creating a Respectful and Open World for Natural Hair │
│ (CROWN) Act was passed only in recent years across select states to │
│ make race-based hair discrimination illegal in employment and schools. │
│ │
│ 3. Generational Habit: Chemical straightening frequently began in early │
│ childhood (ages 4 to 8) as a cultural norm to facilitate hair management.│
│ │
│ 4. Anti-Blame Clinical Principle: Patients should never feel guilt or │
│ embarrassment for past hair practices. Exposure was the result of │
│ societal pressures and unregulated consumer formulations. │
└─────────────────────────────────────────────────────────────────────────────┘
Women who used these products were navigating real economic, professional, and social standards. Medical communication must focus on evidence-based health guidance rather than retrospective judgment.
Clinical Action Plan: What to Do If You Used Relaxers for Years
If you used chemical relaxers or smoothing treatments for years, here is the clear, actionable medical protocol:
┌─────────────────────────────────────────────────────────────────────────────┐
│ CLINICAL DECISION & SYMPTOM GUIDE │
├──────────────────────────┬──────────────────────────────────────────────────┤
│ Scenario │ Recommended Clinical Action │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Asymptomatic Woman │ NO routine screening required. No ultrasound, │
│ (No abnormal bleeding) │ no biopsy. Maintain routine annual well-woman │
│ │ gynecologic exams. │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Postmenopausal Bleeding │ RED FLAG: Any spotting or bleeding after meno- │
│ (Even one drop) │ pause requires URGENT transvaginal ultrasound │
│ │ and endometrial biopsy within 1 to 2 weeks. │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Premenopausal Irregular │ Seek gynecologic evaluation for transvaginal │
│ or Heavy Bleeding │ ultrasound to screen for fibroids, polyps, or │
│ │ endometrial hyperplasia. │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Active Relaxer User │ Practice harm reduction: space treatments to │
│ Wishing to Continue │ 8–12+ weeks, use protective scalp petroleum │
│ │ base, never apply to irritated/scratched scalp. │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Transitioning to Natural │ Transition gradually; explore heat-protective │
│ or Safer Styling │ silk presses, protective braids, or certified │
│ │ formaldehyde-free glyoxylic acid treatments. │
└──────────────────────────┴──────────────────────────────────────────────────┘
For patients navigating pregnancy and breastfeeding who are auditing their personal-care ingredient exposures, see our comprehensive guide on cosmetic ingredients and aesthetic procedures during pregnancy.
Frequently Asked Questions
Do hair relaxers cause cancer?
Epidemiological cohort studies (including the 33,947-woman Sister Study and the Black Women's Health Study) show a statistically significant association between frequent chemical straightener use (>4 times per year) and an increased risk of uterine cancer (hazard ratio 2.55). Because these are observational studies, they demonstrate a correlation and a dose-response relationship, but cannot establish direct biological causation.
Which specific hair relaxers cause cancer?
No scientific study has identified specific brand names. The research collected broad self-reported categories ("straighteners, relaxers, or pressing products") without tracking brand names or ingredient formulas. Lists naming specific brands originate from civil lawsuit filings, not laboratory toxicology or epidemiological data.
Has the FDA banned formaldehyde in hair straighteners?
No. As of August 2026, no FDA ban is in effect. The FDA has an active regulatory agenda item (RIN 0910-AI83) at the Proposed Rule stage to prohibit formaldehyde and formaldehyde-releasing chemicals in heat-activated hair smoothing products, with a target date for issuing the proposed rule of November 2026.
Is there a safe relaxer or alternative?
Traditional chemical relaxers rely on harsh alkaline hydroxides, while heat-activated smoothing treatments frequently release formaldehyde gas. Safer styling alternatives include heat-styling (silk press) using silicone heat protectants, transitioning to natural hair textures, or using verified formaldehyde-free acid-based smoothing treatments (glyoxylic acid) under proper salon ventilation.
Do perms and hair dyes carry the same cancer risk?
No. In the Sister Study, permanent hair dyes, semi-permanent dyes, bleach, and perms (body waves) showed no association with uterine cancer, demonstrating that the risk is specific to chemical straightening and smoothing products.
Does the risk go away if I stopped using relaxers years ago?
While prospective data on risk decline after cessation is limited, reducing exposure to endocrine-disrupting chemicals and eliminating chronic scalp inflammation allows the epidermal barrier to heal, progressively lowering transdermal exposure.
Are keratin treatments and Brazilian blowouts the same as relaxers?
No. Traditional relaxers use highly alkaline hydroxides (pH 12–14) applied to the scalp to permanently break disulfide bonds. Keratin treatments (Brazilian blowouts) use acidic-to-neutral solutions containing formaldehyde or methylene glycol that cross-link keratin when heated with a 450°F flatiron, releasing toxic vapors into the air.
Should I be screened for cancer if I used relaxers for years?
If you have no symptoms, no screening tests (such as routine endometrial biopsies or ultrasounds) are recommended. You should simply maintain regular annual well-woman exams and immediately report any abnormal uterine bleeding or postmenopausal spotting to your gynecologist.
Sources
- PubMed / JNCI — Chang CJ, O'Brien KM, Keil AP, Gaston SA, Jackson CL, Sandler DP, White AJ. Use of Straighteners and Other Hair Products and Incident Uterine Cancer. J Natl Cancer Inst. 2022 Dec 8;114(12):1636-1645 (PMID 36245087): https://pubmed.ncbi.nlm.nih.gov/36245087/
- PubMed / Environmental Research — Bertrand KA, et al. Hair relaxer use and risk of uterine cancer in the Black Women's Health Study. Environ Res. 2023 Dec 15;239(Pt 1):117228 (PMID 37821068): https://pubmed.ncbi.nlm.nih.gov/37821068/
- PubMed / Environmental Health Perspectives — Ogunsina K, et al. Hair Straightener Use in Relation to Prevalent and Incident Fibroids in the Sister Study with a Focus on Black Women. Environ Health Perspect. 2025 Jan;133(1):17004 (PMID 39808082): https://pubmed.ncbi.nlm.nih.gov/39808082/
- PubMed / JNCI — Bailey JT, Chang CJ, Gaston SA, Jackson CL, Sandler DP, et al. Use of hair straighteners and chemical relaxers and incidence of non-reproductive cancers. J Natl Cancer Inst. 2026 Jan 1;118(1):94-101 (PMID 41022397; PMC12487841): https://pubmed.ncbi.nlm.nih.gov/41022397/
- Office of Information and Regulatory Affairs (OIRA) / Reginfo.gov — Unified Agenda Entry RIN 0910-AI83: Use of Formaldehyde and Formaldehyde-Releasing Chemicals as an Ingredient in Hair Smoothing Products or Hair Straightening Products (HHS/FDA, Proposed Rule Stage): https://www.reginfo.gov/public/do/eAgendaViewRule?pubId=202510&RIN=0910-AI83
- Federal Register — Document search for formaldehyde hair smoothing rulemaking (returns no published proposed or final rule as of this article's update date): https://www.federalregister.gov/documents/search?conditions%5Bterm%5D=formaldehyde+hair+smoothing
- National Cancer Institute (NCI) SEER — Cancer Stat Facts: Uterine Cancer (lifetime risk of diagnosis): https://seer.cancer.gov/statfacts/html/corp.html
- ScienceDirect — Safety of chemical hair relaxers: A review article (2024): https://www.sciencedirect.com/science/article/pii/S2950198924000333
- US Food and Drug Administration (FDA) — Hair Smoothing Products That Release Formaldehyde When Heated: https://www.fda.gov/cosmetics/cosmetic-products/hair-smoothing-products-release-formaldehyde-when-heated
